January 24, 2026, 4:06 PM EST. Agilent Technologies has rolled out its S540MD Slide Scanner in Europe, applying AI-assisted tissue detection to speed clinical workflows. The stock has underperformed, with a 90-day return of -8.77% and a 1-year TSR of -10.10%. A valuation view pegs fair value at $168.59, well above the recent $135.05 close, based on a DCF model using a 7.94% discount rate. Analysts point to higher-margin, recurring revenue from consumables, software, services, and digital platforms as a driver of margin expansion and earnings stability via CrossLab. Risks include tariff pressures and slower pharma/replacement cycles. On a price basis, Agilent trades at 29.4x vs peers around 37.7x and a model fair ratio of 23.8x; the stock is labeled undervalued at current prices, though sentiment risk could compress multiples.
